Clarient and ACORN Form Collaboration for Tumor Testing

The agreement will establish a standardized testing protocol across the ACORN network of oncology community practices and hospitals with treatment guidelines and clinical trial opportunities.

Clarient, Inc. and ACORN Research LLC announced their strategic collaboration around molecular testing of tumor samples.

The agreement will establish a standardized testing protocol across the ACORN network of oncology community practices and hospitals with treatment guidelines and clinical trial opportunities. These processes have the potential to improve oncology treatment and research that aim to deliver targeted treatments based on the specific genetic markers for each patient.

The collaboration will establish a system for the collection of a broad array of tumor-specific biomarker data at the time of the patient's initial cancer diagnosis. Clarient's expertise in cancer diagnostics, combined with ACORN's oncology network and advanced bioinformatics platform,